A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

SIMPLE SUMMARY: Despite significant clinical activity, 50% to 70% of patients discontinue ruxolitinib within 3 to 5 years. The identification of patients who are more likely to discontinue it early has now become of paramount practical importance, given the availability of new drugs that are either...

Descripción completa

Detalles Bibliográficos
Autores principales: Palandri, Francesca, Palumbo, Giuseppe A., Bonifacio, Massimiliano, Elli, Elena M., Tiribelli, Mario, Auteri, Giuseppe, Trawinska, Malgorzata M., Polverelli, Nicola, Benevolo, Giulia, Tieghi, Alessia, Cavalca, Fabrizio, Caocci, Giovanni, Beggiato, Eloise, Binotto, Gianni, Cavazzini, Francesco, Miglino, Maurizio, Bosi, Costanza, Crugnola, Monica, Bocchia, Monica, Martino, Bruno, Pugliese, Novella, Venturi, Marta, Isidori, Alessandro, Cattaneo, Daniele, Krampera, Mauro, Pane, Fabrizio, Cilloni, Daniela, Semenzato, Gianpietro, Lemoli, Roberto M., Cuneo, Antonio, Abruzzese, Elisabetta, Branzanti, Filippo, Vianelli, Nicola, Cavo, Michele, Heidel, Florian, Iurlo, Alessandra, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605705/
https://www.ncbi.nlm.nih.gov/pubmed/37894394
http://dx.doi.org/10.3390/cancers15205027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605705/
https://www.ncbi.nlm.nih.gov/pubmed/37894394
http://dx.doi.org/10.3390/cancers15205027

Ejemplares similares